Dicerna Pharmaceuticals Profit Margin

The latest profit margin for DRNA is -64.53% as of September 2021. That compares with -88.81% in the prior-year period — up 27.3% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Dicerna Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, DRNA's profit margin moved from -88.81% to -64.53% — a 27.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Dicerna Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, DRNA currently prints -64.53% for profit margin, while the sector average sits near 13.89%. That is roughly 564.4% below the sector mean. Large gaps often invite a closer look at Dicerna Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Dicerna Pharmaceuticals converts resources into returns. At -64.53%, DRNA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -88.81% in the prior-year period — up 27.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting DRNA's profit margin (-64.53%), review year-over-year change from -88.81%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.